[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595008":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":26,"locations":11,"responsibleParty":33,"collaborators":11,"id":36,"slug":11,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":11,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":11,"enrollmentInfo":44,"targetDuration":11,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":11},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRI-guided Bladder Cancer Preservation Program","EXPERIMENTAL",null,[13],"Radiation: MR-guided Radiation Therapy",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":11},"RADIATION","MR-guided Radiation Therapy",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":23},"Marta Moreno-Jiménez, M.D.",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34 948255400","2772","ucicec@unav.es",{"type":23,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Rafael Martínez Monge","Scientific Director, Radiation Oncology Department","100595008",false,"NCT07026864","MRI-Guided Bladder Preservation Program For Patients With Muscle Invasive Bladder Cancer","Project #1: MRI-guided Bladder Cancer Preservation Program","Inclusion Criteria:\n\n1. Patients with T2-T3N0M0 unifocal bladder cancer of any histologic subtype except squamous cell carcinoma or adenocarcinoma (Janopaul-Naylor et al., 2021) treated the maximal TURBT and able to tolerate concurrent chemoradiotherapy. Selected patients with high risk of common iliac involvement (T4 disease and\u002For limited N+ disease and\u002For LVSI+ status) able to receive the following treatment may be included as well. Additional criteria include:\n2. Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;\n3. WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n1. Prior radiation therapy to the target areas;\n2. Inability to undergo a MRI exam","ALL","18 Years",{"count":45,"type":46},31,"ESTIMATED","INTERVENTIONAL",[49],"NA","The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of bladder preservation as well as to decrease complications in patients with muscle invasive bladder cancer who wish to retain their bladders",[52],"Muscle Invasive Bladder Cancer (MIBC)",[54,55,56,57],"Muscle Invasive Bladder Cancer","Bladder Preservation","Radiation Therapy","MR-Guided Radiation Therapy","NOT_YET_RECRUITING","2025-08-22",{"date":61,"type":62},"2025-08-24","ACTUAL",{"date":64,"type":46},"2025-10-01",{"date":66,"type":46},"2030-07-01",{"name":5,"class":6}]